May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Global Differential and Temporal Transcriptional Profiling of Retinas From AY9944-Treated (SLOS) vs. Control Rats
Author Affiliations & Notes
  • A. M. Siddiqui
    Saint Louis University Sch Med, St. Louis,, Missouri
    Molecular Microbiology & Immunology,
  • M. J. Richards
    Saint Louis University Sch Med, St. Louis,, Missouri
    Ophthalmology and Pharmacol. Physiol. Sci.,
  • S. J. Fliesler
    Saint Louis University Sch Med, St. Louis,, Missouri
    Ophthalmology and Pharmacol. Physiol. Sci.,
  • Footnotes
    Commercial Relationships A.M. Siddiqui, None; M.J. Richards, None; S.J. Fliesler, None.
  • Footnotes
    Support EY007361 (SJF), Research to Prevent Blindness (SJF), and the Norman J. Stupp Foundation Trust (SJF).
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2498. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. M. Siddiqui, M. J. Richards, S. J. Fliesler; Global Differential and Temporal Transcriptional Profiling of Retinas From AY9944-Treated (SLOS) vs. Control Rats. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2498.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Treatment of Sprague Dawley rats with AY9944, an inhibitor of dehydrocholesterol-Δ7-reductase, produces an animal model of Smith-Lemli-Opitz Syndrome (SLOS), including grossly elevated 7-dehydrocholesterol and diminished cholesterol levels in all tissues and progressive retinal degeneration (Fliesler et al., Arch. Ophthalmol. 122:1190, 2004). We analyzed the differential gene expression profiles in retinas from this SLOS rat model compared to age-matched controls.

Methods:: Sprague Dawley rats were treated with AY9944 as previously described (Fliesler et al., 2004) for 1, 2, and 3 mo; control litters (age- and sex-matched) received no drug. All animals were maintained under dim cyclic light (12L:12D, 20-40 lux) and fed a cholesterol-free diet and water ad lib. Total RNA was extracted from individual retinas, and mRNA was amplified and labeled (Affymetrix). Global gene-expression analysis was conducted using Affymetrix GeneChip Rat Genome 230 2.0 high-density arrays (probing 28,000 well-characterized rat genes). Retinas from AY9944-treated rats were compared to age-matched controls (N=3 per condition and age); a two-way ANOVA was performed and gene expression variability evaluated with regard to AY9944 treatment, age, and random noise (P-value ≤ 0.01). Functional category over-representation for each significant gene list was statistically analyzed using EASE/DAVID software (http://david.abcc.ncifcrf.gov).

Results:: ANOVA-derived interaction effects between age and AY9944 treatment yielded 27, 1223, and 544 significant differentially expressed genes at 1, 2, and 3 mo, respectively. EASE/DAVID analysis revealed that genes involved in multiple biochemical pathways are affected, including (among others) fatty acid metabolism, oxidative stress response, cell death/survival, visual transduction, and complement component activation. Notably, sterol metabolism genes were consistently down-regulated at all ages (AY9944 vs. control).

Conclusions:: Retinal degeneration in the SLOS rat model involves differential, age-dependent alterations in multiple genes, with global metabolic involvement not restricted to the sterol pathway. In particular, dramatic gene expression changes occur at 2 mo, a transition point between near-normalcy (1 mo) and obvious histological degeneration and physiological dysfunction (3 mo).

Keywords: gene microarray • degenerations/dystrophies • pathology: experimental 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×